Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Melissa West Lu"'
Autor:
Tod Smeal, Wei Liu, Huichun Zhu, Simon Bailey, Michael R. Collins, A.E. Stewart, Jacqui Elizabeth Hoffman, Lars D. Engstrom, Graham L. Smith, J. Jean Cui, Ya-Li Deng, Benjamin J. Burke, Laura Lingardo, Phuong Le, Andrew Simon Cook, Konstantinos Tsaparikos, Hieu Lam, Jinjiang Zhu, Ted William Johnson, Neal W. Sach, Dac M. Dinh, Robert Louis Hoffman, Mingying He, Hui Wang, Alexei Brooun, Dack Kevin Neil, Qinhua Huang, Sergei Timofeevski, Deal Judith G, Justine L. Lam, Qiuhua Li, Hong Shen, Melissa West Lu, Michele McTigue, Paul F. Richardson, Kevin D. Bunker, Robert Steven Kania, Martin Paul Edwards, Helen Y. Zou, Cynthia Louise Palmer, Patrick S. Johnson
Publikováno v:
Journal of Medicinal Chemistry. 57:1170-1187
Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations
Autor:
Helen Y. Zou, Konstantinos Tsaparikos, Hui Wang, Nathan V. Lee, Justine L. Lam, Qiuhua Li, Ruth W. Tang, Sergei Timofeevski, Tod Smeal, Valeria Fantin, Shinji Yamazaki, Ted William Johnson, Melissa West Lu, Lars R. Engstrom, Hovhannes J. Gukasyan, Wenyue Hu
Publikováno v:
Molecular Cancer Therapeutics. 12:A277-A277
The oncogenic ROS1 gene fusion (Fig-ROS1) was first identified in glioblastoma cells over two decades ago. Recently, ROS1 gene rearrangements were further discovered in a variety of human cancers, including lung adenocarcinoma, cholangiocarcinoma, ov
Autor:
Jinwei Wang, Sergei Timofeevski, Hovhannes J. Gukasyan, Helen Y. Zou, Wenyue Hu, Konstantinos Tsaparikos, Tod Smeal, Qiuhua Li, Hieu Lam, Shinji Yamazaki, Dac M. Dinh, Justine L. Lam, Timothy Affolter, Ted William Johnson, Lars R. Engstrom, Melissa West Lu, Nathan V. Lee, Valeria Fantin, Patrick B. Lappin, Ruth W. Tang, Hui Wang, Jennifer M. Tursi
Publikováno v:
Molecular Cancer Therapeutics. 12:C253-C253
Oncogenic fusions of Anaplastic Lymphoma Kinase (ALK) define a subset of human lung adenocarcinomas. The 1st generation ALK inhibitor XALKORI ® (crizotinib) demonstrated impressive clinical benefit in ALK-fusion positive lung cancers and was approve
Autor:
Lars D. Engstrom, Zheng Feng, Steve Bender, Patrick B. Lappin, Justine L. Lam, Joseph K. T. Lee, Sergei Timofeevski, Qiuhua Li, Brittany A. Snider, Helen Y. Zou, Timothy Nichols, Melissa West Lu, Alex Young, Tod Smeal, Shinji Yamazaki, Sonya Zabludoff, Anthony Wong, Hovhannes J. Gukasyan, James R. Christensen, Dac M. Dinh, Jeffrey Nickel
Publikováno v:
Cancer Research. 71:LB-390
EML4-ALK fusion was recently characterized as an “Addicted Oncogene” in a subset of human lung adenocarcinoma, and it plays an essential role in regulation of the tumor cell survival, growth and metastasis. Crizotinib is a potent and selective AT